Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study
Resource Type
Article
Authors
Kuruvilla, John ; Ramchandren, Radhakrishnan ; Santoro, Armando ; Paszkiewicz-Kozik, Ewa ; Gasiorowski, Robin ; Johnson, Nathalie A ; Fogliatto, Laura Maria ; Goncalves, Iara ; de Oliveira, Jose S R ; Buccheri, Valeria ; Perini, Guilherme F ; Goldschmidt, Neta ; Kriachok, Iryna ; Dickinson, Michael ; Komarnicki, Mieczyslaw ; McDonald, Andrew ; Ozcan, Muhit ; Sekiguchi, Naohiro ; Zhu, Ying ; Nahar, Akash ; Marinello, Patricia ; Zinzani, Pier Luigi
Source
In The Lancet Oncology April 2021 22(4):512-524
Subject
Primary Research Articles
Language
ISSN
1470-2045